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Mephedrone (4-MMC, mephedrone) is a synthetic cathinone derivative included in the
class of new psychoactive substances. It is commonly used simultaneously with alcohol
(ethanol). The aim of the present study was to evaluate the interactions on subjective,
cardiovascular and hormone effects and pharmacokinetics between mephedrone and
alcohol in humans. Eleven male volunteers participated as outpatients in four experimental
sessions in a double-blind, randomized, cross-over, and placebo-controlled clinical trial.
Participants received a single oral dose of 200 mg of mephedrone plus 0.8 g/kg of alcohol
(combination condition); 200 mg of mephedrone plus placebo alcohol (mephedrone
condition); placebo mephedrone plus 0.8 g/kg of ethanol (alcohol condition); and placebo
mephedrone plus placebo alcohol (placebo condition). Outcome variables included
physiological (blood pressure, heart rate, temperature, and pupil diameter),
psychomotor (Maddox wing), subjective (visual analogue scales, Addiction Research
Center Inventory 49 item short form, and Valoración de los Efectos Subjetivos de
Sustancias con Potencial de Abuso questionnaire), and pharmacokinetic parameters
(mephedrone and ethanol concentrations). The study was registered in ClinicalTrials.gov,
number NCT02294266. The mephedrone and alcohol combination produced an increase
in the cardiovascular effects of mephedrone and induced a more intense feeling of
euphoria and well-being in comparison to the two drugs alone. Mephedrone
reduced the sedative effects produced by alcohol. These results are similar to those
obtained when other psychostimulants such as amphetamines and 3,4-
methylenedioxymethamphetamine are combined simultaneously with alcohol. The
abuse liability of mephedrone combined with alcohol is greater than that induced by
mephedrone alone.
Keywords: 4-methylmethcathinone (mephedrone), new psychoactive substance, alcohol (ethanol), interaction,
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During the previous decade, numerous non-conventionally listed
psychoactive compounds, or new psychoactive substances
(NPS), have emerged on the illicit drug market to replace
controlled ones (EMCDDA, 2016). Ease of availability
combined with relatively low prices, and high purity compared
to classical street drugs, plus popularization via Internet-driven
social media, have contributed notably to their increasing
presence on the drug scene. Of the 670 NPS detected by the
European Union’s early warning system, synthetic cathinones
make up the second largest group (ACMD, 2010; Papaseit et al.,
2014; EMCDDA, 2019).
Mephedrone (4-methylmethcathinone, 4MMC, drone, M-CAT,
White Magic, meow meow), also known as “bath salt,” “plant
feeder,” and/or “legal high,” has emerged as a prototypical synthetic
cathinone surpassing the popularity of other NPS (Vardakou et al.,
2011; Bretteville-Jensen et al., 2013). It is a beta-keto amphetamine
analogue, structurally and pharmacological related to 3,4-
methylenedioxymethamphetamine (MDMA) which it was
become its legal alternative (Green et al., 2014; Liechti, 2015). In
vitro pharmacological assays have characterized mephedrone as a
non-selective releaser and inhibitor of their uptake at the
monoamine transporter (Baumann et al., 2012; Simmler et al.,
2013; Baumann et al., 2013; Rickli et al., 2015; Saha et al., 2015).
Recently, initial data regarding the human pharmacology of
mephedrone have confirmed its psychostimulant-like effects
which were first reported by recreational users in forums, surveys,
and naturalistic and observational studies (Dargan et al., 2010;
Winstock et al., 2011; Freeman et al., 2012; Papaseit et al., 2016;
Homman et al., 2018). Following controlled oral administration,
mephedrone induces cardiovascular-stimulant and euphoric effects
with a high abuse liability characterized by earlier onset and shorter
duration in comparison to MDMA and other amphetamine
derivatives (d-amphetamine, methamphetamine and
methylphenidate) (Mayo and de Wit, 2015; Papaseit et al., 2016;
Dolder et al., 2017; Dolder et al., 2018).
In spite of its illicit status, recreational use of mephedrone
continues to be present on the drug scene (Winstock et al., 2011;
Deluca et al., 2012; González et al., 2013; Kelly et al., 2013;
Mixmag’s Drug Survey: The Results, 2014; CSEW, 2018). In
2015, data from the European Drug Report estimated a previous
year prevalence of 3% among club-goers (EMCDDA, 2015). Based
on results from the Crime Survey for England andWales, previous
year use of mephedrone among 16- to 34-year-olds was estimated
at 0.2%; down from 0.5% in 2015/2016, and 1.1% in 2014/15
(CSEW, 2018; EMCCDA, 2018). In the United Kingdom, there
have also been reports of “slamming”—the intravenous injection
of mephedrone and other drugs, such as methamphetamine and
gamma hydroxybutyrate, immediately before/during sex in groups
of men who have sex with men at “chemsex” parties (Melendez-
Torres et al., 2018). Mephedrone injecting has been reported as
occurring mainly among individuals who have previously injected
other drugs (e.g. heroin users), those who have switched from
snorting mephedrone, and among younger users (UNODC, 2017).Frontiers in Pharmacology | www.frontiersin.org 2In addition, mephedrone is linked to an intensive and
repetitive administration pattern in which other drugs are
concomitantly consumed (Schifano et al., 2011; Deluca et al.,
2012). In these social scenes (e.g., nightclubs, music festivals, rave
parties), the use of mephedrone and alcohol is the most common
two-drug combination reported among NPS recreational users
(EMCDDA, 2010; Carhart-Harris et al., 2011; Winstock et al.,
2011). Under these conditions, users often report combining
mephedrone with alcohol to either heighten its effects or
ameliorate the come-down, a particularly unpleasant
experience following mephedrone consumption (Newcombe,
2009; Carhart-Harris et al., 2011; O’Neill and McElrath, 2012).
With respect to acute mephedrone intoxication cases, it is
notable that in 18.2% of cases, alcohol was also present
(EMCDDA, 2016). Indeed, this concomitant use of
mephedrone and alcohol in humans has led to several acute
toxicities (McGaw and Kankam, 2010) and fatalities (Maskell
et al., 2011; Regan et al., 2011; Cosbey et al., 2013; Elliott and
Evans, 2014; Loi et al., 2015; Corkery et al., 2017; Papaseit et al.,
2017). The latest results for acute drug toxicity presentations
from the European Drug Emergencies Network (Euro-DEN)
indicate mephedrone as the most common NPS involved (n =
88). The main acute effects include agitation, anxiety,
palpitations and chest pain. Recently, in Poland an increased
number of acute intoxications with mephedrone (binge episodes)
in combination primarily with alcohol and also other substances
have been detected (Ordak et al., 2018).
Despite the potentially added risks of mephedrone combined
with alcohol, experimental data in humans about interactions
between mephedrone and alcohol are very limited. Experimental
studies in animal models concerning the effects induced after
single and repeated mephedrone and alcohol administration,
demonstrated that alcohol increases stimulant and rewarding
effects of mephedrone (Ciudad-Roberts et al., 2015), and can also
potentiate the neurotoxic properties of mephedrone in
adolescent mice (Ciudad-Roberts et al., 2016). A recent study
has concluded that mephedrone in combination with alcohol
enhances the psychostimulant effect of mephedrone measured as
locomotor activity. Given that both serotonin (5-HT) and
dopamine are also related with reward and impulsivity, the
observed effects point to an increased risk of abuse liability
when combining mephedrone with alcohol compared with the
sole administration of these drugs (López-Arnau et al., 2018). A
part of the present study, including the neurocognitive
performance effects of mephedrone and alcohol, have been
formerly published (de Sousa Fernandes Perna et al., 2016).
The results showed that whilst alcohol intoxication generally
impaired performance, mephedrone improved psychomotor
performance, impaired spatial memory but it did not affect
divided attention performance. Nevertheless, the stimulatory
effects of mephedrone were not enough to compensate for the
impairing effects of alcohol on most performance parameters.
The present study was designed to assess the subjective,
cardiovascular and hormone effects and pharmacokinetics
following the interaction between mephedrone and alcoholJanuary 2020 | Volume 10 | Article 1588
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presented in this paper are part of the previously mentioned
study focusing on the physiological and subjective effects and
pharmacokinetics of both substances.MATERIALS AND METHODS
Subjects
Twelve healthy male subjects were recruited by word of mouth.
Eligibility criteria required the recreational use of amphetamines,
ecstasy, mephedrone, or cathinones with a lifetime minimum of
six times, and on at least two occasions during the year prior to
participation, without any serious adverse reaction; recreational
use of alcohol (less than four units of alcohol per day) and
previous experience of acute alcohol intoxication; and no history
of abuse or drug dependence according to the Diagnosis and
Statistical Criteria for Mental Disorders IV-R for any other
substances except nicotine (in smokers).
All participants completed the study except for one who
dropped out due to personal circumstances after participating
in three experimental sessions (final n = 11). The participants
had a mean age of 28 years (range 22–39 years), mean weight
71.8 kg (range 56.8–83.3 kg), mean height 173.5 cm (range
164.0–180.0 cm) and body mass index 23.8 kg/m2 (range 19.0–
26.8 kg/m2). They had experience with mephedrone (36.4%),
MDMA (90.9%), and cocaine (100%). The participants drank an
average of 2.4 units of alcohol per day (range 1.0–4.0). All but five
were smokers (mean five cigarettes/day, range 2–15).
Prior to their inclusion the participants underwent a general
medical examination, including blood laboratory tests,
urinalysis, 12-lead electrocardiogram (ECG), and a Psychiatric
Research Interview for Substance and Mental Disorders.
Participants completed a training session to familiarize
themselves with testing procedures and questionnaires. In
addition, in order to reduce variability in pharmacokinetics of
mephedrone and to avoid the possibility that subject carriers of
allelic variants leading to the PM phenotype for CYP2D6 might
be at increased risk of acute toxicity, only subjects who were
phenotypically CYP2D6 extensive metabolizers were included
(de la Torre et al., 2005). The protocol was approved by the local
Research Ethics Committee (CEIC-Parc de Salut Mar, Barcelona,
Spain). The study was conducted in accordance with the
Declaration of Helsinki and Spanish laws concerning clinical
tr ials and registered in ClinicalTrials .gov (number
NCT02294266). The volunteers were financially compensated.
Safeguard measures taken to ensure participant welfare while
they were participating in the study included health controls
before each session (a phone call one day before each session to
ensure health status), during sessions (medical examinations at
baseline, clinical monitoring with continuous ECG during 10 h
and a psychiatric evaluation) and after sessions (medical
examination 24 h after each session), a final control including
medical examination and blood and urine chemistry were done
3–7 days after the last session, and a final phone call after 3–
4 weeks.Frontiers in Pharmacology | www.frontiersin.org 3Drugs
Mephedrone was supplied by the Spanish Ministry of Justice and
Ministry of Health. Mephedrone and placebo capsules were
prepared as opaque, white, soft gelatin capsules under the
supervision of the Pharmacy Unit of the Hospital del Mar.
Acute alcohol intoxication was induced by the ingestion of
a beverage containing vodka (Absolut®, Ahus, Sweden) diluted
in lemon-flavored water (Fontvella®) to mask the placebo
drink. The alcohol-placebo drink was lemon-flavored
water (Fontvella®).Study Design
The study was double-blind, double-dummy, randomized, cross-
over, and placebo-controlled. The four drug conditions consisted
of a single oral dose: 200 mg of mephedrone plus 0.8 g/kg of
alcohol (combination condition); 200 mg of mephedrone plus
placebo alcohol (mephedrone condition); placebo mephedrone
plus 0.8 g/kg of alcohol (alcohol condition); and placebo
mephedrone plus placebo alcohol (placebo condition). The
dose of mephedrone was selected based on previous results of
the first study evaluating pharmacological effects of mephedrone
in humans under controlled and experimental administration.
This dose was selected after a series of pilot studies that included
single oral doses of 50, 100, 150, and 200 mg of mephedrone, and
100 mg MDMA, being the dose of 200 mg well tolerated and
produced similar effects to MDMA (Papaseit et al., 2016). The
dose of alcohol and the combination were selected based in
previous psychostimulant drug and alcohol interaction studies
(Farré et al., 1993; Hernández-López et al., 2002).Experimental Sessions
Subjects were admitted to the Clinical Research Unit facilities at
07:45 a.m. after an overnight fast. Upon arrival, they were
questioned about any drug consumption or event that could
affect their participation. They had been requested to refrain
from using any psychoactive drug for a minimum of seven days
prior to the study and throughout it, and from consuming
caffeinated products for 24 h and alcohol for 48 h. A urine
sample was collected for drug testing (Instant-View®, Multipanel
10 Test Drug Screen, Alfa Scientific Designs Inc., Poway, CA-
USA). They remained in a calm and comfortable laboratory
environment during the entire session. Tobacco smoking was not
permitted in the sessions. Last cigarette was allowed 2 h
before admission.
At the beginning of each experimental session baseline
measures were performed. Mephedrone or matched placebo
(one capsule) was administered at 8:30 a.m. in a fasting state
with 100 milliliters (ml) of bottled water (Fontvella®). Alcohol or
matched placebo was administered at 9:00 a.m., 30 min after
mephedrone or matched placebo administration. The total
volume of the beverage (350 ml) was consumed in 15 min
(one-third volume every 5 min).
Four, 6, and 10 h after administration a light breakfast, a meal,
and a snack were provided to the participants/subjects,
respectively. A psychiatric evaluation was performed 8 h afterJanuary 2020 | Volume 10 | Article 1588
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experimental session and the following day.
Physiological Measures
Non-invasive systolic blood pressure (SBP), diastolic blood
pressure (DBP), heart rate (HR), and oral temperature
(T) were repeatedly recorded at: -45 min, 0 h (baseline,
immediately prior to capsule administration), 0.25, 0.5
(immediately prior to beverage administration), 0.75, 1, 1.5, 2,
3, 4, 6, 8, 10, and 24 h following initial drug administration. All
assessments were carried out with a DinamapTM 8100-T vital
signs monitor (Critikon, Tampa, Fla., US). Pupil diameter (PD)
and the Maddox-wing device were recorded at: 0 h (baseline,
immediately prior to capsule administration), 0.25, 0.5
(immediately prior to beverage administration), 0.75, 1, 1.5, 2,
3, 4, 6, 8, 10, and 24 h following initial drug administration.
Pupillary diameter was recorded with a Haab pupil gauge and
Maddox wing measures were expressed in diopters along the
device’s horizontal scale. The Maddox-wing device measures the
balance of extraocular muscles and quantifies exophoria as an
indicator of extraocular muscle relaxation, and esophoria as an
indicator of extraocular muscle tension. For safety reasons ECG
was continuously monitored along 10 h using a DinamapTM
Plus vital signs monitor (Critikon, Tampa, Fla., US).
Subjective Effects
Subjective effects were measured using a set of 23 visual analogue
scales (VAS), the 49-item Addiction Research Center Inventory
short form (ARCI), the Evaluation of Subjective Effects of
Substances with Abuse Potential questionnaire (VESSPA-SEE),
and a pharmacological class identification questionnaire.
VAS (100 mm) were labeled at opposite ends with different
adjectives ranging from “not at all” to “extremely” (Farré et al.,
2004; Peiró et al., 2013; Farré et al., 2015; Papaseit et al., 2016).
Subjects were asked to rate effects from among “high,”
“drunkenness,” “stimulated,” “any effect,” “good effects,” “bad
effects,” “liking,” “content,” “drowsiness,” “dizziness,”
“confusion,” “fear,” “depression or sadness,” “changes in
distances,” “changes in colors,” “changes in shapes,” “changes
in lights,” “hallucinations-seeing of lights or spots,” “changes in
hearing,” “hallucinations-hearing sounds or voices,”
“hallucinations-seeing animals, things, insects or people,”
“different or changed unreal body feeling,” and “different or
unreal surroundings”.
The Spanish validated version of the short-form ARCI
(Lamas et al., 1994), which consists of a true/false 49-item
questionnaire, it is a validated instrument for determining
subjective drug effects including five subscales: PCAG
(pentobarbital-chlorpromazine-alcohol group, a measure of
sedation); MBG (morphine-benzedrine group, a measure of
euphoria); LSD (lysergic acid diethylamide group, a measure
of dysphoria and somatic symptoms); BG (benzedrine group, a
stimulant subscale relating to intellectual efficiency and energy);
and A (amphetamine, a measure of d-amphetamine effects)
(Farré et al., 2015).
The VESSPA-SEE is a questionnaire that measures changes in
subjective effects caused by different drugs including MDMA. ItFrontiers in Pharmacology | www.frontiersin.org 4includes six subscales: sedation (S), psychosomatic anxiety
(ANX), changes in perception (CP), pleasure and sociability
(SOC), activity and energy (ACT), and psychotic symptoms
(PS) (Poudevida et al., 2003; Papaseit et al., 2016).
The pharmacological class identification questionnaire asks
about the class of drugs the participants believed they had been
given at each administration (Rush et al., 1995). The options
included placebo, benzodiazepine (e.g., valium, diazepam,
tranxilium, rophipnol), alcohol, stimulant (amphetamine),
designer drugs (ecstasy), cocaine, hallucinogen (e.g., LSD,
mescaline), cannabinoids (e.g., marijuana, hashish), ketamine
(special K), and gamma hydroxybutyrate (liquid ecstasy).
The VAS were administered at: -45 min (baseline), 0.25, 0.5
(immediately prior to beverage administration), 0.75, 1, 1.5, 2, 3,
4, 6, 8, 10, and 24 h following initial drug administration. ARCI
and VESSPA-SEE were administered at: -45 min, 0.25, 0.5 1.5, 2,
3, 4, 6, 8, and 10 h following initial drug administration. The
pharmacological class identification questionnaire was given at 8
h following initial drug administration.Pharmacokinetics
Blood samples for the determination of mephedrone were
collected during each experimental session at -5 min (0 h,
baseline), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 h
following drug administration. Urine was collected until 24 h
(data not shown). Mephedrone plasma concentrations were
quantified by gas chromatography-mass spectrometry (GC-
MS). A liquid–liquid extraction was performed with tert-butyl
methyl etherm and the silylation reagent [N-methyl-N-
(trimethylsilyl) trifluoroacetamide] was used for the
derivatization of mephedrone (Papaseit et al., 2016; Olesti
et al., 2017).
Blood samples for the determination of alcohol were collected
during each experimental session at -5 min (0 h, baseline), 0.75,
1, 1.5, 2, 3, 4, 6, 8, and 10 h after drug administration. Urine was
collected until 24 h (data not shown). Alcohol plasma
concentrations were determined with an enzymatic test (DRI
Ethyl Alcohol Assay, Thermo Scientific) in an autoanalyzer
(Indiko Plus, Thermo Fisher Scientific).
Blood samples for the determination of cortisol were collected
during each experimental session at -5 min (0 h, baseline), 1, 2, 4,
6, and 8 h following drug administration. They were centrifuged
at 3,000 rpm for 10 min at 4°C, plasma and serum were removed
and frozen at -220°C until analysis. Cortisol plasma
concentrations were determined by fluorescence polarization
immunoassay (Abbott Laboratories, Chicago, IL) according to
the manufacturer’s instructions (Kobayashi et al., 1979).
Statistical Analysis
Statistical analysis was performed for eleven participants.
Values from physiological and subjective effects were
transformed to differences from baseline. The peak effects in
the first 6 h after first drug administration (maximum absolute
change from baseline values, Emax), and the 6-h area under the
curve (AUC) of effects versus time were calculated by the
trapezoidal rule for each variable.January 2020 | Volume 10 | Article 1588
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concentrations (Tmax) from mephedrone, alcohol and cortisol
plasma concentrations were determined using PKSolver, a freely
available add-in program for Microsoft Excel (Joel Usansky, Atul
Desai, and Diane Tang-Liu, Department of Pharmacokinetics
and Drug Metabolism, Allergan, Irvine, CA, USA). Area under
the concentration-time curve from mephedrone, alcohol and
cortisol (AUC0-6), mephedrone (AUC0-24), and alcohol
(AUC0-10) were calculated by the linear trapezoidal rule.
Firstly, these transformations were analyzed using a two-way
analysis of variance (ANOVA) test to study the influence of some
participant factors as age, body mass index, weight, smoking and
alcohol use in the different parameters calculated. Because the
results showed only marginal statistically significant results for
factors/interactions, the analysis was rejected (11 variables showed
significant results for a total number of 200 comparison,
percentage 5.5%). Subsequently, the statistical analysis presented
was performed without considering those factors.
Then, these transformations were analyzed by means of one-
way repeated-measures analysis of variance (ANOVA) with drug
condition as factor. In case of significant differences among
treatment conditions in ANOVA, post-hoc multiple comparisons
were performed using the Tukey test. Time course (T-C) of effects
was analyzed employing two-way repeated-measures ANOVA
with Treatment condition and Time (0–6 h) as factors. When
Treatment condition, or the Treatment condition × Time
interaction, were statistically significant, multiple Tukey post-hoc
comparisons were performed at each time point. The difference in
time to reach peak effects (Tmax) values among conditions was
assessed with the nonparametric Friedman test. When significant
results among conditions were detected post-hoc multiple
comparison was performed applying the Wilcoxon signed rank
test adjusting the p value to six comparisons (p < 0.008).
All statistical tests were performed at each time point using
the PASW Statistics 18.0 (SPSS Inc., Chicago, IL, USA). A value
of p < 0.05 was considered statistically significant.RESULTS
Global Results
Table 1 shows the summary of physiological and subjective
effects where at least one statistical difference (peak, AUC) was
found in the ANOVA and multiple comparison post-hoc test
analyses. Furthermore, it includes T-C points that presented
significant differences in ANOVA and the multiple-comparison
post-hoc tests. Table 2 shows the Peak effect values of variables
where at least one statistical difference was found in the ANOVA.
The T-C (differences from baseline) for the most relevant
physiological, psychomotor, and subjective effects are shown in
Figures 1 and 2, respectively. Concentrations over time and
pharmacokinetic parameters of mephedrone and alcohol in
plasma are presented in Figure 3 and Table 3, respectively.
The effects of all drug/experimental conditions on plasma
cortisol levels are depicted in Tables 1 and 2.Frontiers in Pharmacology | www.frontiersin.org 5No serious adverse events were observed. No hallucinations,
psychotic episodes, or any other psychiatric symptoms were
experienced during the sessions. None of the participants
required specific therapy or special care during the study. All
11 subjects completed the study.
Physiological Effects
Regarding physiological effects, the two conditions including
mephedrone (combination condition and mephedrone
condition) produced an increase in SBP, DBP, HR, and PD as
compared with the placebo condition (when considering both
peak effects and AUC). The more relevant differences for HR
increase appeared between the combination and mephedrone
conditions. The former produced an increase of 40 ± 17 beats per
min (bpm) at 1 h following the first drug administration whilst
for the latter the peak effects was 32 ± 20 bpm at 0.75 h. In
statistical terms, only significant differences were detected for
AUC0-6 (142.33 mm × h for the combination condition, and 70.91
mm × h for the mephedrone one) and T-C points (1.5–6 h) for
both. For the remaining physiological variables (SBP, DBP, T,
and PD), only significant differences in several T-C points were
observed between the combination and mephedrone conditions
(no AUC or peak effects).
The alcohol condition produced very slight effects on SBP,
DBP, HR, and T and none on DP compared with the placebo
condition (non-statistically significant). Comparing the
combination and alcohol condition, the mephedrone-alcohol
effects on SBP, DBP, HR and DP were significantly higher than
those produced by alcohol alone (when considering both peak
effects and AUC) with significant differences at several
T-C points.
In the Maddox-wing device, the combination and
mephedrone conditions led to an increase in the degree of
esophoria compared with placebo (when considering peak
effects and/or AUC). Esophoria induced by the combination
condition was approximately two to three-fold lower (-1.41 ±
2.91 diopters) in comparison with the mephedrone one (-3.45 ±
2.73 diopters) with only significant differences in several T-C
points (1–1.5 h). Alcohol slightly increased exophoria (+1.41 ±
1.30 diopters), relaxation of ocular musculature, but only
significant differences in several T-C points were obtained
when compared with the placebo. The combination condition
scored approximately midway between the mephedrone and
alcohol conditions.
Subjective Effects
The two conditions containing mephedrone caused an increase
in subjective effects (VAS, ARCI, and VESSPA-SEE) compared
with placebo (Tables 1 and 2).
The combination andmephedrone conditions led to significant
changes in the ratings of “high,” “stimulated,” “any effect,” “good
effects,” “liking,” “content” and also in “change in distances and
different, changed or unreal body feeling” in comparison with
placebo. In general terms, the combination condition produced
higher and more prolonged scores with statistically significantJanuary 2020 | Volume 10 | Article 1588





















































































**TABLE 1 | Summary of statistically significant results of the physiological parameters and subjective effects (n = 11) observed after administration of mephedrone
placebo alcohol (mephedrone), placebo mephedrone plus alcohol (alcohol), and placebo mephedrone plus placebo alcohol (placebo condition).
Variable Tukey’s Multiple Comparison Test (*p < 0.05; **p <
ANOVA Placebo Mep
Parameter F/X2 p Value Alcohol Mephedrone Mephedrone–alcohol Alcohol
Physiological effects
SBP AUC (df = 3,30) 22.107 <0.001 NS ** ** **
Peak (df = 3,30) 38.667 <0.001 NS ** ** **
Tmax 11.97 0.007 NS NS * NS
T-C (df = 3,270) 13.924 <0.001 0.75*,4* 0.5**,0.75**,1**, 1.5**,2**,3** 0.5**,0.75**,1**, 1.5**,2**,3** 0.5**,0.75**,1**,
1.5**,2**,3**,4**
DBP AUC (df = 3,30) 17.087 <0.001 NS ** ** **
Peak (df = 3,30) 20.138 <0.001 NS ** ** **
Tmax 9.54 0.023 NS NS NS NS
T-C (df = 3,270) 5.526 <0.001 6* 0.5*,0.75**,1**,1.5**,2** 0.5**,0.75**,1**, 1.5**,2** 0.5**,0.75**,1**,
1.5**,2**,3*,4**,6**
HR AUC (df = 3,30) 25.960 <0.001 NS ** ** NS
Peak (df = 3,30) 23.570 <0.001 NS ** ** **
Tmax 9.38 0.025 NS * NS NS





T AUC (df = 3,30) 6.475 0.002 NS ** NS *
Peak (df = 3,30) 1.420 0.252
Tmax 2.93 0.402
T-C (df = 3,270) 4.598 <0.001 0.75** 1.5**,2**,3**,4**, 6** 0.75**,1**,2**,4**,6** 0.75**,1.5**,2**,3**,4**
PD AUC (df = 3,30) 20.973 <0.001 NS ** ** **
Peak (df = 3,30) 25.333 <0.001 NS ** ** **
Tmax 14.24 0.003 NS * NS NS
T-C (df = 3,270) 8.972 <0.001 0.5*,0.75**,1**, 1.5**,2* 0.5**,0.75**,1**,1.5**, 2**, 3** 0.5*,0.75**,1**,1.5**,2
Maddox-wing AUC (df = 3,30) 7.674 0.001 NS NS NS **
Peak (df = 3,30) 13.1320 <0.001 NS ** NS **
Tmax 6.21 0.102
T-C (df = 3,270) 4.585 <0.001 1**,1.5*,4* 0.75**,1**,1.5**,2* 0.75**,1* 0.5**,0.75**,1**,1.5**,2**,3
Visual Analogue Scales
High AUC (df = 3,30) 14.998 <0.001 NS NS ** NS
Peak (df = 3,30) 27.105 <0.001 NS ** ** **
Tmax 28.39 <0.001 NS * * NS
T-C (df = 3,270) 10.564 <0.001 0.5**,0.75**, 1**,1.5**,2* 0.75**, 1**, 1.5**, 2**,3**, 4** 0.5**, 0.75**, 1**, 1.5**
Drunkenness AUC (df = 3,30) 20.076 <0.001 ** NS ** **
Peak (df = 3,30) 30.600 <0.001 ** NS ** **
Tmax 30.12 <0.001 * NS * *
T-C (df = 3,270) 8.780 <0.001 0.75**,1**,1.5**,2**,3** 0.75**,1**,1.5**,2**,3* 0.75**,1**,1.5**, 2**,3
Stimulated AUC (df = 3,30) 9.434 <0.001 NS NS ** NS
Peak (df = 3,30) 17.026 <0.001 * ** ** NS
Tmax 23.69 <0.001 * * * NS
T-C (df = 3,270) 5.568 <0.001 0.75**, 1**,1.5** 0.5**,0.75**,1**,1.5** 0.5**,0.75**,1**,1.5**,2**,3** 0.5**,0.75**
Any effect AUC (df = 3,30) 13.702 <0.001 ** NS ** NS
Peak (df = 3,30) 21.813 <0.001 ** ** ** NS
Tmax 24.38 <0.001 * * * NS
T-C (df = 3,270) 6.411 <0.001 0.75**,1**,1.5**,2** 0.5**,0.75**,1**,1.5** 0.5**,0.75**,1**, 1.5**,2**,3** 0.5**




































































Variable Tukey’s Multiple Comparison Test (*p < 0.05; **p < 0
ANOVA Placebo Meph
Parameter F/X2 p Value Alcohol Mephedrone Mephedrone–alcohol Alcohol
Good effects AUC (df = 3,30) 14.115 <0.001 NS NS ** NS
Peak (df = 3,30) 22.754 <0.001 NS ** ** *
Tmax 19.21 <0.001 * * * NS
T-C (df = 3,270) 6.173 <0.001 1**.1.5* 0.5**,0.75**,1**, 1.5**,2** 0.25**,0.5**,0.75**,
1**,1.5**,2**,3**
0.75**,1*,1.5*
Bad effects AUC (df = 3,30) 3.426 0.030 *
Peak (df = 3,30) 2.384 0.089
Tmax 8.29 0.040 NS NS NS NS
T-C (df = 3,270) 1.164 0.268
Liking AUC (df = 3,30) 12.629 <0.001 NS NS ** NS
Peak (df = 3,30) 15.248 <0.001 NS ** ** *
Tmax 17.67 0.001 NS * * NS
T-C (df = 3,270) 5.756 <0.001 0.5*,0.75**,1**, 1.5** 0.5**,0.75**,1**, 1.5**,2**,3** 0.5*,0.75**,1**
Content AUC (df = 3,30) 10.094 <0.001 NS NS ** NS
Peak (df = 3,30) 16.287 <0.001 ** ** ** NS
Tmax 22.4 <0.001 * * * NS
T-C (df = 3,270) 4.726 <0.001 1**,1.5**,2* 0.75**,1**,1.5**, 2* 0.5**,0.75**,1**, 1.5**,2**,3** 0.75**
Drowsiness AUC (df = 3,30) 6.629 0.001 ** NS NS **
Peak (df = 3,30) 5.383 0.004 ** NS NS *
Tmax 14.73 0.002 NS NS NS NS
T-C (df = 3,270) 2.117 <0.001 2*,3**,4** 6* 2**,4**
Dizziness AUC (df = 3,30) 3.375 0.031 * NS NS NS
Peak (df = 3,30) 3.055 0.043 * NS NS NS
Tmax 13.13 0.004 NS NS NS NS
T-C (df = 3,270) 1.521 0.052
Confusion AUC (df = 3,30) 2.347 0.093
Peak (df = 3,30) 2.395 0.088
Tmax 8.10 0.044 NS NS NS NS
T-C (df = 3,270) 1.679 0.022 0.5*,0.75*,2** 0.5**,0.75**,1**, 1.5**,2* 2**
Changes in
Distances
AUC (df = 3,30) 2.071 0.125
Peak (df = 3,30) 1.530 0.226
Tmax 9.87 0.020 NS NS NS NS
T-C (df = 3,270) 1.513 0.054
Changes in Colors AUC (df = 3,30) 3.184 0.038 NS NS * NS
Peak (df = 3,30) 2.310 0.096
Tmax 6.38 0.095
T-C (df = 3,270) 1.352 0.120
Changes in lights AUC (df = 3,30) 2.880 0.052
Peak (df = 3,30) 2.652 0.067
Tmax 7.03 0.071
T-C (df = 3,270) 1.661 0.024 1* 0.5**,0.75**,1**, 1.5**,2**
Changes in hearing AUC (df = 3,30) 1.102 0.364
Peak (df = 3,30) 1.574 0.216
Tmax 7.32 0.062
T-C (df = 3,270) 1.587 0.037 0.5**,0.75**,1* 0.5**,0.75**,1*
Different body
feeling
AUC (df = 3,30) 4.905 0.007 NS NS ** NS
Peak (df = 3,30) 7.766 0.001 NS ** ** NS
Tmax 14.43 0.002 NS NS * NS
T-C (df = 3,270) 3.535 <0.001 0.5**,0.75**,1** 0.5**,0.75**,1**, 1.5**,2**,3** 0.5**,0.75**,1**.0
e
















































































Variable Tukey’s Multiple Comparison Test (*p < 0.05; **p <
ANOVA Placebo Me
Parameter F/X2 p Value Alcohol Mephedrone Mephedrone–alcohol Alcohol
Different
surroundings
AUC (df = 3,30) 1.426 0.255
Peak (df = 3,30) 2.147 0.115
Tmax 9.04 0.029 NS NS NS NS
T-C (df = 3,270) 1.243 0.195
ARCI questionnaire subscales
ARCI-PCAG AUC(df = 3,30) 12.704 <0.001 ** NS NS **
Peak (df = 3,30) 6.992 0.001 ** NS NS *
Tmax 11.64 0.009 * NS NS NS
T-C (df = 3,150) 6.992 <0.001 1.5*,2**,3**,4**,6** 1.5**,2*,6** 1.5**,2**,3**,4**,6*
ARCI-MBG AUC (df = 3,30) 20.441 <0.001 NS * ** NS
Peak (df = 3,30) 23.217 <0.001 NS ** ** *
Tmax 18.88 <0.001 * * * NS
T-C (df = 3,150) 11.162 <0.001 1.5**,2** 1.5**,2**,3**,4* 1.5**,2**
ARCI-LSD AUC (df = 3,30) 3.787 0.020 NS NS * NS
Peak (df = 3,30) 3.290 0.034 NS NS NS NS
Tmax 15.43 0.001 * NS * NS
T-C (df = 3,150) 2.357 0.005/
0.025
1.5**,2**,3** 1.5** 1.5**,2**,3*,4** 3*
ARCI-BG AUC (df = 3,30) 13.389 <0.001 NS NS * **
Peak (df = 3,30) 12.759 <0.001 NS NS ** **
Tmax 14.90 0.001 * NS * NS
T-C (df = 3,150) 5.124 <0.001 3** 1.5** 1.5**,2**,3** 1.5**,2**,3**,4*
ARCI-A AUC (df = 3,30) 17.750 <0.001 NS ** ** *
Peak (df = 3,30) 24.674 <0.001 NS ** ** *
Tmax 17.60 0.001 NS * * NS
T-C (df = 3,150) 9.197 <0.001 1.5* 1.5**,2**,3* 1.5**,2**,3**,4** 1.5**,2**
VESSPA questionnaire subscales
VESSPA-S AUC (df = 3,30) 7.671 0.001 ** NS NS **
Peak (df = 3,30) 9.517 <0.001 ** NS * *
Tmax 21.03 <0.001 * * * NS
T-C (df = 3,150) 2.989 <0.001 1.5**, 2**,3**,4**,6** 6** 1.5**, 2**,3**,4*,6*
VESSPA-ANX AUC (df = 3,30) 28.198 <0.001 NS ** ** *
Peak (df = 3,30) 31.959 <0.001 NS ** ** **
Tmax 21.51 <0.001 * * * NS
Time Course (df =
3,150)
20.031 <0.001 1.5**,2**,3** 1.5**,2**,3**,4**,6** 1.5**,2**,3*
VESSPA-CP AUC (df = 3,30) 3.445 0.029 NS NS NS NS
Peak (df = 3,30) 3.604 0.025 NS NS NS NS
Tmax 8.88 0.031 NS NS NS NS
T-C (df = 3,150) 2.159 0.010 1.5**,2**,3* 1.5**,2**,3** 1.5**,2*,3*
VESSPA-SOC AUC (df = 3,30) 11.817 <0.001 NS ** ** NS
Peak (df = 3,30) 13.779 <0.001 NS ** ** NS
Tmax 16.53 0.001 NS NS NS NS
T-C (df = 3,150) 8.619 <0.001 1.5**,2* 1.5**,2** 1.5**,2**,3**,4* 1.5**
VESSPA-ACT AUC (df = 3,30) 15.151 <0.001 NS NS ** NS
Peak (df = 3,30) 20.330 <0.001 NS ** ** NS
Tmax 15.03 0.002 * NS NS NS
T-C (df = 3,150) 10.297 <0.001 1.5** 1.5**,2** 1.5**,2**,3**,4* 1.5***
*
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Frontiers in Pharmacology | www.frontiersin.org 9differences in AUC and several T-C points compared with
mephedrone alone. In addition, for “stimulated,” “any effect,”
“good effects,” “liking,” and “content” scores these differences
were statistically significant for peak effects and, in the case of
“high,” also for Tmax. As expected, statistically significant
differences were detected in drunkenness rating scores between
conditions (AUC, peak, Tmax, and T-C, Tables 1 and 2).
The alcohol condition produced an increase in the ratings of
“drunkenness,” “content,” “stimulated,” “any effect,” “good
effects,” and “liking” compared with placebo (Table 2).
Regarding “drunkenness,” the most characteristic effect for
alcohol, a no significant lower score was observed for the
combination condition in comparison to the alcohol condition
(peak effect 34.18 ± 21.53 vs 49.36 ± 25.70 mm, respectively;
Table 2), but significant differences, however, were only found at
several T-C points (0.75–1.5 h). In contrast, significant
differences were detected for “content” effects in AUC, peak
effects, and T-C points (0.5–3 h) with higher scores in the
combination condition compared with the alcohol one (Tables
1 and 2).
In the ARCI questionnaire, both conditions including
mephedrone produced an increase in the scores of MBG
(euphoria), BG (intellectual efficiency and energy) (Tables 1
and 2), A (amphetamine-like effects), and LSD (dysphoria)
subscales in comparison to placebo (when considering AUC,
peak effects, and both). The MBG, BG, and A peak scores were
10.36 ± 3.91, 3.82 ± 3.52, and 6.55 ± 2.73 points for the
combination condition and 6.45 ± 5.80, 2.64 ± 2.94, and 4.82 ±
2.79 points for the mephedrone condition, respectively. For
MBG, significant differences were detected in AUC, peak
effects, and several T-C points (1.5–3h) between conditions.
For the other subscales only significant differences were
detected at several T-C points. Conversely, for the LSD
subscale no significant differences were detected between
both conditions.
Alcohol produced a statistically significant increase in the
PCAG-sedation subscale in comparison to placebo. Compared
with the alcohol condition, the combination with mephedrone
reduced the sedation induced by alcohol (peak effect 6.18 ± 3.60
vs 5.26 ± 1.58) with statistical differences in peak effects and AUC
that remained statistically significant during 2.5 h in the T-C
analysis (1.5–4 h). In contrast, MBG peak difference scores were
lower for alcohol compared to the combination condition (2.27 ±
1.62 vs 10.36 ± 3.91, respectively) with statistical differences in
peak effects, AUC, and T-C analysis (1.5–3 h) (Tables 1 and 2).
Regarding the VESSPA-SEE questionnaire, the combination
and mephedrone conditions increased all the subscales
compared with placebo. The combination condition, in
comparison to the mephedrone one, presented statistical
differences in peak effects for ACT (activity and energy) and
ANX (psychosomatic anxiety) subscales and in several T-C
points for all the subscales (Tables 1 and 2). With respect to
the alcohol condition, statistical differences in peak effects, AUC,
and T-C points for ANX, SOC, (pleasure and sociability) and
ACT subscales and only in peak effects for CP subscale were
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Papaseit et al. Mephedrone and AlcoholIn the pharmacologic drug class identification questionnaire,
the combination condition (mephedrone plus alcohol) was
correctly identified by all subjects (100% designer drug and
100% alcohol). For the mephedrone condition (mephedrone
plus placebo), mephedrone was identified by eight subjects as a
designer drug (72.7%), as a stimulant (18.2%) by two, and as
placebo (9.1%) by one, whilst placebo was identified correctly by
all the subjects (100%). With respect to the alcohol/placebo
alcohol conditions, the placebo was identified as such by nine
subjects (81.8%), and as a designer drug (9.1%) and cannabinoids
(9.1%) by one subject each, whilst alcohol was identified correctly
by all subjects (100%).
All the active conditions (mephedrone, alcohol, and the
combination) were well tolerated and no mania, hallucinations
or psychotic reactions were observed or reported during
the study.Frontiers in Pharmacology | www.frontiersin.org 10Pharmacokinetic Measures
Mephedrone and Alcohol Concentrations
The pharmacokinetic parameters for mephedrone and alcohol
are summarized in Table 3 and Figure 3.
When the two conditions containing mephedrone were
compared, no significant differences were found in the
pharmacokinetic parameters (Table 3). In the combination
condition, mephedrone concentrations peaked at 1.5 h. In the
mephedrone condition, mephedrone concentrations peaked at
1.5 h. In both conditions, at 10 h following first drug
administration, mephedrone concentrations declined to mean
values of 15.73 and 12.76 ng/ml until undetectable levels at 24 h,
respectively (Figure 3).
Regarding alcohol, significant differences in pharmacokinetics
were detected. Alcohol concentrations peaked at 2 h (in the
combination condition and at 1.5 h in the alcohol one.TABLE 2 | Summary of Peak effects (maximal effect, mean value and standard error) for physiological, subjective and cortisol concentrations (Cmax) (n = 11).
Placebo Alcohol Mephedrone Mephedrone + alcohol
Physiological effects
SBP -5.82 ± 2.96 -5.00 ± 4.52 35.45 ± 4.28 40.36 ± 3.57
DBP 0.27 ± 3.10 -1.73 ± 3.86 19.64 ± 2.08 22.45 ± 1.83
HR -7.18 ± 2.28 9.91 ± 4.35 32.27 ± 6.03 40.09 ± 5.25
T -0.94 ± 0.12 -0.47 ± 0.14 -0.56 ± 0.21 -0.56 ± 0.16
PD 0.00 ± 0.00 0.00 ± 0.00 1.64 ± 0.35 1.91 ± 0.33
Maddox-wing 0.00 ± 0.27 1.41 ± 0.39 -3.45 ± 0.82 -1.41 ± 0.88
Visual Analogue Scales
High 0.00 ± 0.00 1.55 ± 1.55 47.36 ± 9.31 55.09 ± 7.90
Drunkenness 0.00 ± 0.00 49.36 ± 7.75 0.00 ± 0.00 34.18 ± 6.49
Stimulated 0.00 ± 0.00 23.00 ± 5.77 42.73 ± 8.56 53.18 ± 8.17
Any effect 0.00 ± 0.00 49.91 ± 7.40 51.18 ± 9.27 56.09 ± 7.68
Good effects 0.00 ± 0.00 23.18 ± 5.20 51.09 ± 8.59 63.36 ± 8.49
Bad effects 0.00 ± 0.00 14.18 ± 7.26 3.45 ± 2.06 4.55 ± 2.05
Liking 0.00 ± 0.00 17.18 ± 7.19 44.09 ± 8.59 50.27 ± 8.31
Content 0.00 ± 0.00 30.91 ± 6.73 43.64 ± 8.24 56.09 ± 8.16
Drowsiness 8.45 ± 2.62 29.09 ± 8.14 12.36 ± 4.81 17.00 ± 3.95
Dizziness 0.00 ± 0.00 20.27 ± 8.07 6.18 ± 5.70 11.36 ± 8.00
Confusion 0.00 ± 0.00 20.64 ± 7.67 11.00 ± 5.85 15.73 ± 9.29
Changes in Distances 0.00 ± 0.00 11.55 ± 6.14 11.64 ± 6.53 13.09 ± 6.78
Changes in Colors 0.00 ± 0.00 4.73 ± 2.46 6.27 ± 3.45 8.55 ± 3.84
Changes in lights 0.00 ± 0.00 6.36 ± 2.76 6.64 ± 4.11 11.64 ± 5.73
Changes in hearing 0.00 ± 0.00 3.18 ± 1.58 14.18 ± 9.29 6.27 ± 4.13
Different body feeling 0.00 ± 0.00 13.27 ± 5.21 30.91 ± 9.01 33.18 ± 9.67
Different surroundings 0.00 ± 0.00 9.91 ± 5.39 10.73 ± 3.61 15.36 ± 7.80
ARCI questionnaire subscales
ARCI-PCAG 1.00 ± 0.65 6.18 ± 1.09 2.82 ± 1.19 1.73 ± 1.58
ARCI-MBG 0.09 ± 0.09 2.27 ± 0.49 6.45 ± 1.75 10.36 ± 1.18
ARCI-LSD -0.45 ± 0.25 1.55 ± 0.85 0.73 ± 0.74 1.55 ± 0.96
ARCI-BG 0.00 ± 0.23 -2.27 ± 0.54 2.64 ± 0.89 3.82 ± 1.06
ARCI-A 0.27 ± 0.14 2.00 ± 0.47 4.82 ± 0.84 6.55 ± 0.82
VESSPA questionnaire subscales
VESSPA-S 1.09 ± 1.09 9.36 ± 2.49 4.27 ± 1.47 6.09 ± 1.40
VESSPA-ANX 0.00 ± 0.00 1.55 ± 0.41 9.00 ± 1.72 12.36 ± 1.46
VESSPA-CP 0.00 ± 0.00 1.64 ± 0.65 0.45 ± 0.25 1.91 ± 0.91
VESSPA-SOC 0.09 ± 0.09 4.09 ± 1.46 7.36 ± 2.22 13.00 ± 1.73
VESSPA-ACT 0.27 ± 0.19 4.36 ± 0.96 8.18 ± 2.14 12.55 ± 1.52
VESSPA-PS 0.00 ± 0.00 0.64 ± 0.39 1.27 ± 0.45 2.45 ± 0.87
Cortisol 14.93 ± 4.50 16.20 ± 4.88 22.23 ± 6.70 23.85 ± 7.19January 2020 |SBP: systolic blood pressure, mm; DBP: diastolic blood pressure, mmHg; HR: heart rate, beats per minute; T: temperature, °C; PD: pupil diameter, mm; visual analogue scale, mm, ARCI:
Addiction Research Center Inventory [ARCI], score; VESSPA: Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire, score.
Only statistically significant results are showed (see Table 1 for comparisons). Conditions are mephedrone plus alcohol (mephedrone–alcohol), mephedrone plus placebo alcohol
(mephedrone), placebo mephedrone plus alcohol (alcohol), and placebo mephedrone plus placebo alcohol (placebo).Volume 10 | Article 1588
Papaseit et al. Mephedrone and AlcoholSignificant differences in AUC were detected between alcohol and
combination conditions.
Cortisol Concentrations
Kinetic parameters for cortisol are summarized in Tables 1 and
2. Plasma cortisol concentrations were significantly higher (peak
and AUC) after the administration of the combination and
mephedrone conditions as compared with placebo.
Cortisol concentrations peaked at 2 h with a mean peak of
23.85 ± 1.31 µg/dl after the combination condition and 22.23 ±
1.23 µg/dl after mephedrone administration. The combination
condition also showed significant differences in comparison
to alcohol, cortisol concentrations peaked at 2 h with a
mean peak of 16.20 ± 0.82 µg/dl. AUC for combination,
mephedrone and alcohol conditions were 96.05, 87.29 and
62.31 ng/ml·h1, respectively.
Significant differences in peak, AUC and several T-C points (1
and 2 h) were observed between the combination and
mephedrone conditions in comparison to placebo, and alsoFrontiers in Pharmacology | www.frontiersin.org 11between alcohol and the combination conditions in
comparison to mephedrone.DISCUSSION
To the best of our knowledge, this study provides the first
data in humans about the pharmacodynamics and
pharmacokinetics of mephedrone and alcohol interactions and
completes previous results on neurocognitive performance
effects (de Sousa Fernandes Perna et al., 2016). Our findings
demonstrate the increased pharmacological effects of the co-
administration of mephedrone and alcohol compared to single
drug administration.
The 200 mg oral administration of mephedrone reproduced
pharmacological effects which concurred with the sole
experimental study performed to date in humans (Papaseit
et al, 2016). Our results demonstrate that mephedrone
produced a significant increase in BP, HR, and PD. It alsoFIGURE 1 | Time course of drug effects (n = 11, mean, standard error) on physiological and psychomotor performance (differences from baseline). □ mephedrone +
alcohol; ○mephedrone; ◊ alcohol; D placebo; Significant differences between mephedrone vs mephedrone + alcohol (a: p < 0.05/A: p < 0.01); alcohol vs
mephedrone + alcohol (b: p < 0.05/B: p < 0.01).January 2020 | Volume 10 | Article 1588
Papaseit et al. Mephedrone and AlcoholFIGURE 2 | Time course of drug effects (n = 11, mean, standard error) on subjective effects (differences from baseline). □ mephedrone + alcohol; ○ mephedrone;
◊ alcohol; D placebo; Significant differences between mephedrone vs mephedrone + alcohol (a: p < 0.05/A: p < 0.01); alcohol vs mephedrone + alcohol (b: p <
0.05/B: p < 0.01).Frontiers in Pharmacology | www.frontiersin.org January 2020 | Volume 10 | Article 158812
Papaseit et al. Mephedrone and Alcoholinduced stimulant-like effects (euphoria, well-being, feelings of
pleasure) and mild changes in perceptions. All these
physiological and subjective effects were of rapid onset and
short duration. The increase in VAS scores (stimulated, high,
good effects, liking) and ARCI (subscales MBG, BG, and A)
caused by mephedrone were within the range of previous studies
with psychostimulant drugs with a well-known abuse potential
(Farré et al., 1993; Hernández-López et al., 2002). Moreover, its
faster and shorter duration confirmed results obtained in the
previous human investigation (Papaseit et al., 2016). The
administration of an oral dose of 0.8 g/kg of alcohol replicated
the typical effects of acute alcohol intoxication characterized by
an increase in the ratings of drunkenness, sedation, and mild
effects on physiological responses compared with placebo.
The co-administration of mephedrone and alcohol amplified
cardiovascular effects, producing a more marked increase in HR in
comparison with mephedrone alone. In turn, these results are
consistent with a previous description of cardiovascular toxicity
associatedwithmephedrone and alcohol co-ingestion (McGawand
Kankam, 2010). Similar findings have also been observed after the
concomitant administration of other psychostimulants drugs
(MDMA, methamphetamine, cocaine) in combination with
alcohol in healthy volunteers (Pérez-Reyes and Jeffcoat, 1992;
Farré et al., 1993; Higgins et al., 1993; McCance-Katz et al., 1993;Frontiers in Pharmacology | www.frontiersin.org 13Mendelson et al., 1995; Hernández-López et al., 2002; Dumont
et al., 2010).
In addition, the combination of mephedrone and alcohol
produced mydriasis and esophoria, an indicator of extraocular
muscle tension, two specific acute psychostimulant-like effects,
although slighter in comparison to mephedrone alone. These
results are in line with those observed after other psycho-
stimulant drugs and alcohol co-administration (Mas et al.,
1999; de la Torre et al., 2000; Farré et al., 2015). Alcohol, as
expected from the extrapolation of results obtained from other
psychostimulant-alcohol interaction studies, attenuated the rise
in PD and extraocular musculature contraction induced by
mephedrone. Furthermore, the addition of alcohol to
mephedrone increased the maximal psychostimulant effects,
maintaining higher measures for euphoria and well-being for a
longer period of time in comparison to mephedrone alone, which
maximal effects are faster (Papaseit et al., 2016). Among
conditions, the most remarkable difference was in the
mephedrone-alcohol combination. It produced during 4 h
relevant increases in subjective scores which were intense
during the three first hours compared with 1–2 h following
mephedrone alone.
Alcohol administration, equivalent four to six alcoholic
beverages, in combination with mephedrone resulted inFIGURE 3 | Plasma concentration over time curves of mephedrone (left) and ethanol (right) (n = 11, mean, standard error). ○ mephedrone; ◊ alcohol;
□ mephedrone + alcohol.TABLE 3 | Pharmacokinetics parameters of mephedrone and alcohol in plasma (n = 11).
Pharmacokinetic parameters Cmax (ng/ml) AUC0-6 (ng/ml h
-1) AUC0-24 (ng/ml h
-1) Tmax (h) Ke (h-1) t1/2 (h)
Mephedrone
Mephedrone and ethanol 175.7 ± 71.1 516.8 ± 264.6 709.8 ± 477.1 1.5 (0.75–2) 0.35 ± 0.14 2.32 ± 1.01
Mephedrone 172.6 ± 82.9 549.0 ± 315.0 778.4 ± 512.9 1.5 (0.5–2) 0.29 ± 0.09 2.68 ± 0.92
p-value NS NS NS NS NS NS
Cmax (ng/ml) AUC0-6 (ng/ml h
-1) AUC0-10 (ng/ml h
-1) Tmax (h)
Ethanol
Mephedrone and ethanol 103.8 ± 14.1 389.8 ± 73.3 447.0 ± 96.8 2.0 (1.5–2)
Ethanol 121.1 ± 14.9 438.4 ± 36.8 512.9 ± 45.2 1.5 (1–2)
p-value 0.030 0.048 0.020 0.014January 2020 | Volume 10 |AUC: area under the curve. SD: standard deviation. Tmax is shown as median (range) values. NS: not statistically significant. A value of p < 0.05 was considered statistically significant.Article 1588
Papaseit et al. Mephedrone and Alcoholdecreased drunkenness and reduced sedative effects producing
mixed scores (ARCI-PCAG and VAS drowsiness) between the
mephedrone and alcohol alone conditions. Mephedrone
moderated the effects induced by alcohol in a similar manner
to that observed after MDMA experimental administration
(Hernández-López et al., 2002).
Overall, the combination of mephedrone and alcohol slightly
delayed peak effects and increased maximal effects which
remained high with no changes in their total duration.
Cardiovascular and subjective effects after mephedrone-alcohol
co-administration started at 0.25–5 h, peaked at approximately
0.75–1.5 h after administration, and returned to pre-dose values
at 4–8 h after administration with approximately 3–4 h of
marked effects. In general terms, mephedrone induced lower
effects than the combination and almost overlapped with our
own observations in a previous study in which the same dose of
mephedrone was administered (Papaseit et al., 2016).
Mephedrone effects were observed between 0.5-1 h and most
returned to baseline 2–3 h after drug administration, but some
last more than 3 h (HR, temperature, stimulated or any effect).
With respect to the pharmacokinetics of the mephedrone-
alcohol combination, the most relevant finding was that alcohol
did not modify the plasma levels of mephedrone. The maximal
concentrations of mephedrone after the combination
administration were within the range of those obtained after
mephedrone alone and concurred with previously published data
(Papaseit et al., 2016). This finding suggests that the
pharmacokinetics of mephedrone is not altered when alcohol is
concurrently administered.
With reference to alcohol pharmacokinetics, statistically
significant differences were detected in Cmax, AUC, and Tmax.
In this respect, other psychostimulant-alcohol studies have also
reported slightly lower alcohol Cmax in combination conditions
related to changes in alcohol metabolism and absorption rate
(Farré et al., 1993; McCance-Katz et al., 1993). In the case of
mephedrone, initial results suggest a similar kinetic scenario.
An adequate pharmacological effect in relation to
pharmacokinetics was thus observed despite the biological
variability among subjects. Our results suggest that the higher
abuse liability exhibited for mephedrone when concomitantly
consumed with alcohol can be attributed to the early onset and
maintenance of the subjective/pleasant effects in comparison to
mephedrone alone. It should be emphasized that the short
mephedrone half-life and Tmax following its co-administration
with alcohol could partially explain the mephedrone-alcohol
binge pattern among regular users.
Higher increases in cortisol plasma concentrations were found
after the mephedrone-alcohol co-administration and mephedrone
alone in comparison to the rest of conditions. This pattern of
response has already been observed after cocaine and alcohol
(Farré et al., 1997) and MDMA and alcohol administration
(Hernández-López et al., 2002). Interestingly, both combinations
with alcohol, and also MDMA and cocaine alone, produced
significant cortisol increases (Farré et al., 1997; Harris et al.,
2002; Hernández-López et al., 2002; Kuypers et al., 2013;
Kuypers et al., 2015). As far as we know, the precise mechanismFrontiers in Pharmacology | www.frontiersin.org 14of this effect is poorly understood. Although the role of cortisol in
the acute effects of mephedrone has as yet to be described, it could
be extrapolated to MDMA and related-amphetamines (Mas et al.,
1999). The serotonergic effects of mephedrone might stimulate the
hypothalamo-pituitary-adrenal axis, leading to an increase in
cortisol plasma concentrations as previously described by other
psychostimulants as MDMA (Seibert et al., 2014; Papaseit et al.,
2016; Strajhar et al., 2019).
Integrating the results of the present study and the previous
one on psychomotor performance (de Sousa Fernandes Perna
et al., 2016), it seems that mephedrone reduced some of the
subjective feelings of sedation induced by alcohol, but its
stimulatory effects were not enough to compensate for the
impairing effects of alcohol on most performance parameters.
This dissociation between subjective and objective sedation
measures is of interest. Subjects may feel less sedated by alcohol
and psychomotor abilities remain impaired or unchanged. The
potential impact of this dissociation in terms of driving safety is
unknown, but it may be plausible that subjects would consider
they are driving better when actual performance continues to be
impaired by the effect of alcohol. Similar dissociation has been
reported when other psychostimulants (e.g. cocaine, MDMA)
have been administered simultaneously with alcohol (Farré et al.,
1993; Farré et al., 1997; Hernández-López et al., 2002).
The present study has several limitations which are mainly
associated with its experimental design. Firstly, the moderate
sample size. Secondly, a non-representative sample that not
allows to generalize the results across gender (absence of
women due to unknown and potential seriously fetal risk).
Thirdly, the evaluation of only one dose level of mephedrone
and alcohol (users usually are subjected to repeated drug
consumption in a single session). Fourthly, the alcohol blind
was potentially insufficient. Nonetheless, we conducted a placebo
controlled study, randomized, within-subjects, various control
conditions (combination condition, mephedrone condition,
alcohol condition, and placebo condition). The results provide
novel data on pharmacodynamics and pharmacokinetics of
mephedrone-alcohol combination.
In summary, the concomitant administration of mephedrone
and alcohol produced a significant increase in cardiovascular
effects and induced more intense and prolonged feelings of
euphoria and well-being, in comparison to mephedrone alone.
Mephedrone reduced the drunkenness and sedation produced by
alcohol. These effects could encourage the consumption of larger
amounts of mephedrone and alcohol, placing the recreational
user at a heightened risk for potentially toxic effects. The results
presented are like those obtained with the combination of
alcohol and other psychostimulants, suggesting that the abuse
liability of the simultaneous consumption is greater than that
induced by mephedrone alone.DATA AVAILABILITY STATEMENT
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